A
AMYLYX PHARMACEUTICALS INC
NASDAQ: AMLX (Amylyx Pharmaceuticals, Inc.)
Last update: 13 minutes ago12.46
-0.78 (-5.89%)
| Previous Close | 13.24 |
| Open | 12.73 |
| Volume | 2,404,623 |
| Avg. Volume (3M) | 1,706,001 |
| Market Cap | 1,329,076,224 |
| Price / Sales | 0.660 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | 16,317.06% |
| Diluted EPS (TTM) | -3.10 |
| Quarterly Revenue Growth (YOY) | -99.60% |
| Total Debt/Equity (MRQ) | 0.69% |
| Current Ratio (MRQ) | 12.05 |
| Operating Cash Flow (TTM) | -206.98 M |
| Levered Free Cash Flow (TTM) | -182.62 M |
| Return on Assets (TTM) | -40.72% |
| Return on Equity (TTM) | -83.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Amylyx Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 9.54% |
| % Held by Institutions | 85.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2025 | 8,800,000 |
| Perceptive Advisors Llc | 30 Jun 2025 | 7,902,365 |
| Tcg Crossover Management, Llc | 30 Jun 2025 | 5,943,812 |
| Blackrock, Inc. | 30 Jun 2025 | 5,510,189 |
| Point72 Asset Management, L.P. | 30 Jun 2025 | 4,536,266 |
| Vanguard Group Inc | 30 Jun 2025 | 4,498,028 |
| Saturn V Capital Management Lp | 30 Jun 2025 | 3,260,570 |
| Fmr Llc | 30 Jun 2025 | 3,048,019 |
| Nantahala Capital Management, Llc | 30 Jun 2025 | 2,934,405 |
| 683 Capital Management, Llc | 30 Jun 2025 | 2,160,000 |
| Almitas Capital Llc | 30 Jun 2025 | 2,122,597 |
| Great Point Partners I Lp | 30 Jun 2025 | 2,000,000 |
| Geode Capital Management, Llc | 30 Jun 2025 | 1,692,413 |
| Millennium Management Llc | 30 Jun 2025 | 1,512,058 |
| Goldman Sachs Group Inc | 30 Jun 2025 | 1,297,982 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Guggenheim, 100.64%) | Buy |
| Median | 20.00 (60.51%) | |
| Low | 16.00 (B of A Securities, 28.41%) | Buy |
| Average | 20.00 (60.51%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 13.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Oct 2025 | 20.00 (60.51%) | Buy | 14.95 |
| Baird | 16 Oct 2025 | 19.00 (52.49%) | Buy | 15.17 |
| B of A Securities | 03 Oct 2025 | 16.00 (28.41%) | Buy | 13.42 |
| 28 Aug 2025 | 14.00 (12.36%) | Buy | 9.42 | |
| Goldman Sachs | 16 Sep 2025 | 20.00 (60.51%) | Buy | 11.96 |
| Guggenheim | 15 Sep 2025 | 25.00 (100.64%) | Buy | 11.85 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences |
| 30 Oct 2025 | Announcement | Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 10 Sep 2025 | Announcement | Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock |
| 09 Sep 2025 | Announcement | Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 27 Aug 2025 | Announcement | Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) |
| 26 Aug 2025 | Announcement | Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |